Mabpharm Limited (2181.HK)

HKD 0.3

(-4.76%)

Total Debt Summary of Mabpharm Limited

Mabpharm Limited's latest annual total debt in 2023 was 260.07 Million CNY , up 105.86% from previous year.
Mabpharm Limited's latest quarterly total debt in 2024 Q2 was 193.82 Million CNY , up 25.69% from previous quarter.
Mabpharm Limited reported annual total debt of 126.33 Million CNY in 2022, up 176.51% from previous year.
Mabpharm Limited reported annual total debt of 45.69 Million CNY in 2021, up 13.24% from previous year.
Mabpharm Limited reported quarterly total debt of 193.82 Million CNY for 2024 Q2, up 25.69% from previous quarter.
Mabpharm Limited reported quarterly total debt of 265.57 Million CNY for 2023 Q3, up 80.09% from previous quarter.

Annual Total Debt Chart of Mabpharm Limited (2023 - 2017)

Historical Annual Total Debt of Mabpharm Limited (2023 - 2017)

Year	Total Debt	Total Debt Growth
2023	260.07 Million CNY	105.86%
2022	126.33 Million CNY	176.51%
2021	45.69 Million CNY	13.24%
2020	40.34 Million CNY	-61.8%
2019	105.62 Million CNY	0.59%
2018	105 Million CNY	40.0%
2017	75 Million CNY	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	193.82 Million CNY	-25.47%
2024 Q2	193.82 Million CNY	25.69%
2023 Q3	265.57 Million CNY	80.09%
2023 Q2	147.47 Million CNY	-17.01%
2023 Q1	177.7 Million CNY	40.66%
2023 Q4	260.07 Million CNY	-2.07%
2023 FY	260.07 Million CNY	105.86%
2022 Q1	113.6 Million CNY	148.65%
2022 FY	126.33 Million CNY	176.51%
2022 Q3	158.04 Million CNY	24.76%
2022 Q2	126.68 Million CNY	11.51%
2022 Q4	126.33 Million CNY	-20.06%
2021 FY	45.69 Million CNY	13.24%
2021 Q4	45.69 Million CNY	23.0%
2021 Q3	37.14 Million CNY	-0.94%
2021 Q1	32.66 Million CNY	-19.05%
2021 Q2	37.49 Million CNY	14.8%
2020 Q4	40.34 Million CNY	26.73%
2020 FY	40.34 Million CNY	-61.8%
2020 Q2	40.5 Million CNY	20.28%
2020 Q1	33.67 Million CNY	-68.12%
2020 Q3	31.83 Million CNY	-21.4%
2019 Q1	134.26 Million CNY	27.87%
2019 FY	105.62 Million CNY	0.59%
2019 Q4	105.62 Million CNY	4.83%
2019 Q3	100.75 Million CNY	-29.01%
2019 Q2	141.93 Million CNY	5.71%
2018 FY	105 Million CNY	40.0%
2018 Q1	- CNY	0.0%
2018 Q4	105 Million CNY	-11.06%
2018 Q3	118.05 Million CNY	0.0%
2017 FY	75 Million CNY	0.0%

Peer Total Debt Comparison of Mabpharm Limited

Name	Total Debt	Total Debt Difference
Uni-Bio Science Group Limited	52.86 Million HKD	-391.938%
CK Life Sciences Int'l., (Holdings) Inc.	5.93 Billion HKD	95.615%